M&A / Deals Aligos and Xiamen Amoytop sign deal for HBV therapy Pharmaceutical TechnologyAligos Therapeutics and Xiamen Amoytop Biotech are to develop and commercialise pevifoscorvir sodium in Greater China for chronic HBV infection.M&A / DealsRead full story pharminent April 17, 2026 (Last updated: April 17, 2026) Pharmaceutical Technology Aligos Therapeutics and Xiamen Amoytop Biotech are to develop and commercialise pevifoscorvir sodium in Greater China for chronic HBV infection. M&A / DealsRead full story Post navigation Previous: The innovators working to make in vivo cell therapy a realityNext: Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
